Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CP-526, 555 · 4 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| CP-526,555 (varenicline) | DRUG | - |
Inclusion Criteria: * Cigarette smokers who are motivated to stop smoking and have smoked an average of at least 10 cigarettes per day Exclusion Criteria: * Subjects who have used a nicotine replacement product within 30 days of the study screening visit or intend to use it during the study.
CP-526,555 is an investigational small molecule being developed for smoking cessation. It is in Phase 2 clinical development and has been studied in four completed trials enrolling a total of 2,150 participants. The drug is not approved and remains under clinical investigation.
CP-526,555 is being developed by Pfizer, Inc., which trades under the ticker PFE. The company has sponsored four Phase 2 clinical trials of the drug for smoking cessation, all of which have been completed.
CP-526,555 is in Phase 2 clinical development. All four of its clinical trials are Phase 2 studies and have been completed. The drug is investigational and has not been approved by regulatory authorities for any use.
CP-526,555 has been studied in four completed Phase 2 trials: NCT00139750 (600 participants in Japan), NCT00150228 (300 participants in the US), NCT00150241 (625 participants in the US), and NCT00150254 (625 participants in the US). All trials evaluated the drug for smoking cessation.
CP-526,555 is the investigational code name for the drug that was later developed as varenicline, marketed as Chantix. The clinical trials listed under CP-526,555 are the Phase 2 studies that evaluated this compound for smoking cessation.